Detailed dose evidence documented for Octreotide in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
Acromegaly — SC: 50–100 mcg three times daily initially, then LAR: 10–30 mg IM q4wk. Carcinoid syndrome — SC: 100–600 mcg/day in 2–4 divided doses; LAR: 20–30 mg IM q4wk. VIPoma — SC: 200–300 mcg/day in 2–4 divided doses; LAR 20–30 mg IM q4wk. (LAR requires SC overlap for 2 weeks after first IM dose.)
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
PROMID: octreotide LAR 30 mg IM q4wk for NET disease control.
Not established
What is not established
Effects on tumor size, growth, or metastases — not established in the US label for octreotide; PROMID disease-control data are supported but off-label in the US.
Efficacy in pancreatic NET not demonstrated (PROMID excluded pancreatic primary).
No established role in obesity, diabetic complications, or other off-label metabolic uses.